Moderna
MRNA
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
The Motley Fool • 4 days ago • MRNA
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally
Accesswire • 11 days ago • MRNA
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Reuters • 11 days ago • MRNA
Moderna's mRNA flu vaccine outperforms standard shot in late-stage trial
24/7 Wall Street • 13 days ago • MRNA
Pfizer vs Moderna: Only One Pharma Giant Is a Winner In The Post-Covid Era
Seeking Alpha • 16 days ago • MRNA
Moderna, Inc. (MRNA) Q1 2026 Earnings Call Transcript
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.